Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Operating Expenses: 2012-2024

Historic Operating Expenses for Coherus Oncology (CHRS) over the last 13 years, with Dec 2024 value amounting to $378.6 million.

  • Coherus Oncology's Operating Expenses rose 5.66% to $55.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $370.4 million, marking a year-over-year increase of 11.11%. This contributed to the annual value of $378.6 million for FY2024, which is 17.77% down from last year.
  • Coherus Oncology's Operating Expenses amounted to $378.6 million in FY2024, which was down 17.77% from $460.4 million recorded in FY2023.
  • In the past 5 years, Coherus Oncology's Operating Expenses ranged from a high of $590.4 million in FY2021 and a low of $319.5 million during FY2020.
  • Its 3-year average for Operating Expenses is $435.7 million, with a median of $460.4 million in 2023.
  • Per our database at Business Quant, Coherus Oncology's Operating Expenses spiked by 84.79% in 2021 and then fell by 20.75% in 2022.
  • Over the past 5 years, Coherus Oncology's Operating Expenses (Yearly) stood at $319.5 million in 2020, then skyrocketed by 84.79% to $590.4 million in 2021, then decreased by 20.75% to $467.9 million in 2022, then decreased by 1.60% to $460.4 million in 2023, then decreased by 17.77% to $378.6 million in 2024.